

Joint Working

Executive Summary

Project title	Primary Care Initiation of Anticoagulation Project - North Central & North East London
Project partners	UCL Partners Academic Health Science Network Bayer plc Daiichi Sankyo
Project summary	<p>The project aims to support the development and confidence of GPs to initiate anticoagulation and associated service models to enable CCGs to commission primary-care anticoagulation services using GPs as prescribers.</p> <p>This project has two linked aims; to support the development and confidence of GPs to initiate anticoagulation treatment (as this has traditionally been done by others in the service); and to develop primary care anticoagulation service models involving GPs and using UCL Partners principles of sustainability, developing this further to transfer to other clinicians outside secondary care.</p> <p>Project objectives:</p> <ol style="list-style-type: none">1) Create an integrated care pathway for anticoagulation that is supported by clinical engagement across primary and secondary care2) Increase the number of patients with newly identified AF who are anticoagulated by GPs thus reducing the waiting times for anticoagulation across the CCG3) Test 2-3 different models of initiating anticoagulation and evaluate their impact both on clinicians and patients4) Develop a support package for roll out as part of the pan-London AF improvement programme

Expected benefits to patients, the NHS and Bayer

Benefits for Patients

- Care closer to home
- Reduction in waiting times for anticoagulation initiation
- Prevention of serious incidents (which may have been caused by delay in anticoagulation initiation)

Benefits for NHS/UCL Partners Stakeholders

- Reduced mortality – this will be implemented as part of the pan-London AF programme which aims to save 350-450 lives over 5 years and prevent over 300 strokes prevented per annum. (calculated using QOF data from 2014-2015)
- Promote integrated working across clinical boundaries
- More patients receiving NICE recommended treatment for AF in a timely manner
- Developing skills of prescribers

Benefits for Industry Partners

Appropriate NICE approved anti-coagulation medicines including the company's medicines, delivered to more patients in line with national guidelines; including but not limited to NICE Clinical Guideline CG180 Atrial Fibrillation: management, NICE TA256 Rivaroxaban, NICE TA355 Edoxaban NICE TA249 Dabigatran, NICE TA341 Apixaban, for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation.

Start date

May 2017